Skip to main content

Table 1 Demographic and clinical characteristics of the CHB patients

From: Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls

  

HBeAg

hepatic steatosis

Total (n = 1185)

Positive (n = 658)

Negative (n = 527)

n = 273

P

Age

Median years

33 (15–67)

31 (15–60)

37 (17–67)

36 (16–67)

 

Means ± SD

33 ± 9

31 ± 8A

37 ± 9A

36 ± 9

< .001A

Sex

Female

291 (25%)

180 (27%)B

111 (21%) B

43 (16%)C

.012B

Male

894 (75%)

478 (73%)B

416 (79%)B

230 (84%)C

< .001C

ALT (U/L)

Means ± SD

153 ± 218

169 ± 216D

133 ± 220D

 

.005D

TBIL (μmol/L)

< 17 μmol/L (n)

1010 (85%)

    

17–50 μmol/L (n)

166 (14%)

    

51–100 μmol/L (n)

6 (0.5%)

    

101–150 μmol/L (n)

3 (0.25%)

    

HBV DNA (log10 IU/L)

Means ± SD

5.97 ± 1.96

6.77 ± 1.14E

4.97 ± 1.43E

 

< .001E

Hepatic steatosis

273 (23%)

131 (20%)F

142 (27%)F

 

.004E

  1. Continuous variables are presented as the mean (SD) if normally distributed and median if not. Significant differences among them are reported as P values. A,B C,D,ESignificant differences (P ≤ .05) between groups are indicated as follows:
  2. AFor comparison between HBeAg-positive and HBeAg-negative patients
  3. BFor comparison of females and males who were HBeAg positive and HBeAg negative
  4. CFor comparison of CHB with hepatic steatosis between females and males
  5. DFor comparison of ALT between HBeAg-positive and HBeAg-negative patients
  6. FFor comparison of CHB with hepatic steatosis between HBeAg-positive and HBeAg-negative patients